Publications by authors named "Carla Perna"

Claim this Profile
P
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.
Pasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, Guillermo Villacampa, Fay Cafferty, Carla Perna

Eur Urol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Regard to Crook et al.
Christos Mikropoulos, Mohamed Metawe, Sophie Otter, Carla Perna, Sheel Mehta

Int J Radiat Oncol Biol Phys· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic Magnetic Resonance-Guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer: Acute and Late Patient-Reported Toxicity Outcomes.
Killian Nugent, Prantik Das, Dan Ford, Ami Sabharwal, Carla Perna

Adv Radiat Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC).
Elena Moreno-Olmedo, Ami Sabharwal, Prantik Das, Nicola Dallas, Daniel Ford, Carla Perna

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Net survival of men with localized prostate cancer after LDR brachytherapy.
Santiago Uribe-Lewis, Jennifer Uribe, Claire Deering, Suzanne Langley, Donna Higgins, Carla Perna

Brachytherapy· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes.
Sarah Benafif, Ann-Britt Jones, Susan Merson, Reshma Rageevakumar, Eva McGrowder, Carla Perna

BJC Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?
Stephen Langley, Jennifer Uribe, Santiago Uribe-Lewis, Sheel Mehta, Christos Mikropoulos, Carla Perna

Brachytherapy· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Nicholas D James, Noel W Clarke, Adrian Cook, Adnan Ali, Alex P Hoyle, Carla Perna

Int J Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Nicholas D James, Fiona C Ingleby, Noel W Clarke, Claire L Amos, Gerhardt Attard, Carla Perna

JNCI Cancer Spectr· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival after low-dose-rate brachytherapy for prostate cancer: the Royal Surrey experience.
Santiago Uribe-Lewis, Jennifer Uribe, Vincent Bourke, Claire Deering, Donna Higgins, Carla Perna

BJU Int· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.
Stephen Langley, Christopher Eden, Matthew Perry, Krishna Patil, Dimitrios Moschonas, Carla Perna

BJU Int· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Hannah L Rush, Laura Murphy, Alicia K Morgans, Noel W Clarke, Adrian D Cook, Carla Perna

J Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Regard to Parry et al.
Stephen Langley, Robert Laing, Sara Khaksar, Carla Perna, Sophie Otter

Int J Radiat Oncol Biol Phys· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure.
Jennifer Uribe, Santiago Uribe-Lewis, Sara Khaksar, Carla Perna, Christos Mikropoulos

BJUI Compass· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer.
Stephen Langley, Jennifer Uribe, Santiago Uribe-Lewis, Adrian Franklin, Carla Perna

BJU Int· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials.
Marcas M Bamman, Gary R Cutter, David M Brienza, John Chae, Daniel M Corcos, Carla G Perna

Arch Phys Med Rehabil· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
Robert Laing, Jennifer Uribe, Santiago Uribe-Lewis, Julian Money-Kyrle, Carla Perna

BJU Int· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
Stephen E M Langley, Ricardo Soares, Jennifer Uribe, Santiago Uribe-Lewis, Julian Money-Kyrle, Carla Perna

BJU Int· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis